Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Liver transplant patients may dodge kidney failure with simple drug infusion

NCT ID NCT04592744

First seen Sep 30, 2025 · Last updated Jun 11, 2026 · Updated 36 times

Summary

This study tests whether giving a drug called angiotensin 2 during liver transplant surgery can prevent acute kidney injury, a common and serious complication. About 30 adults with end-stage liver disease will be randomly assigned to receive either the drug plus standard care or standard care alone during their operation. Researchers will track kidney function and complications for up to 28 days after surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative Medicine

    Los Angeles, California, 90095, United States

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver End Stage Liver Disease acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.